AF
KYMR icon

Allworth Financial’s Kymera Therapeutics KYMR Stock Holding History

Allworth Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.34K Sell
64
-2
-3% -$172 ﹤0.01% 3919
2026
Q1 		$5.5K Buy
66
+22
+50% +$1.74K ﹤0.01% 3906
2025
Q4 		$3.42K Hold
44
– – ﹤0.01% 3911
2025
Q3 		$2.49K Buy
44
+6
+16% +$271 ﹤0.01% 3908
2025
Q2 		$1.66K Sell
38
-14
-27% -$482 ﹤0.01% 3788
2025
Q1 		$1.75K Buy
52
+23
+79% +$838 ﹤0.01% 3262
2024
Q4 		$1.28K Hold
29
– – ﹤0.01% 3321
2024
Q3 		$1.37K Hold
29
– – ﹤0.01% 3108
2024
Q2 		$1.25K Hold
29
– – ﹤0.01% 3093
2024
Q1 		$1.17K Hold
29
– – ﹤0.01% 3032
2023
Q4 		$739 Buy
+29
New +$519 ﹤0.01% 3043
2023
Q3 		– Sell
-113
Closed -$2.6K – 3493
2023
Q2 		$2.6K Sell
113
-6
-5% -$172 ﹤0.01% 2377
2023
Q1 		$3.53K Buy
119
+100
+526% +$3.23K ﹤0.01% 2178
2022
Q4 		$474 Sell
19
-3
-14% -$80 ﹤0.01% 2645
2022
Q3 		$0 Buy
+22
New +$580 ﹤0.01% 2893

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Allworth Financial's KYMR Position: Q2 2026 in Review

Allworth Financial reduced its Kymera Therapeutics (KYMR) stake by 3% in Q2 2026, selling an estimated $172 and leaving 64 shares worth $7.34K. The position accounts for ﹤0.01% of the portfolio, ranked #3919.

Allworth Financial first reported a position in KYMR in Q3 2022 and has held it in 15 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Allworth Financial held 64 shares of Kymera Therapeutics worth $7.34K as of Q2 2026.
  • Allworth Financial sold 2 Kymera Therapeutics shares in Q2 2026, an estimated $172.
  • Kymera Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3919 holding.
  • Allworth Financial first reported a position in Kymera Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.